Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

Respiratory Medicine

Volumn 108, Issue 4, 2014, Pages 584-592

  Beeh, Kai Michael ^a   Korn, Stephanie ^b   Beier, Jutta ^a   Jadayel, Dalal ^c   Henley, Michelle ^c   D'Andrea, Peter ^d   Banerji, Donald ^d  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Novartis Horsham Research Center   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Exercise; Hyperinflation; QVA149; Tiotropium

Indexed keywords

GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; GLYCOPYRRONIUM BROMIDE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BACKACHE; BODY PLETHYSMOGRAPHY; BORG SCORE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CONTROLLED STUDY; CONTUSION; COUGHING; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPNEA; ENDURANCE; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HEADACHE; HUMAN; HYPERINFLATION; INHALER; INSPIRATORY CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SCORING SYSTEM; SLOW VITAL CAPACITY; SPIROMETRY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; LUNG VOLUME; PATHOPHYSIOLOGY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; INDANS; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SCOPOLAMINE DERIVATIVES; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84896080720     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.01.006     Document Type: Article

References (32)

1. D.E. O'Donnell Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease Proc Am Thorac Soc 3 2 2006 Apr 180 184
2. GOLD Global Initiative for Chronic Obstructive Lung Disease (GOLD).Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease update 2013 [accessed on 22.03.13] www.goldcopd.org/uploads/ users/files/GOLD-Report-2013-Feb19.pdf
3. E.D. Bateman, G.T. Ferguson, N. Barnes, N. Gallagher, Y. Green, and M. Henley et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur Respir J 42 2013 Dec 1484 1494
4. J.A. Wedzicha, M. Decramer, J.H. Ficker, D.E. Niewoehner, S. Thomas, and A. FowlerTaylor et al. Analysis of COPD exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study Lancet Respir Med 1 2013 May 199 209
5. R. Dahl, K. Chapman, M. Rudolf, R. Mehta, P. Kho, and V. Alagappan et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study Respir Med 107 2013 Oct 1558 1567
6. B. Balint, H. Watz, C. Amos, R. Owen, M. Higgins, and B. Kramer Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone Int J Chron Obstruct Pulmon Dis 5 2010 Sep 7 311 318
7. R. Buhl, L.J. Dunn, C. Disdier, C. Lassen, C. Amos, and M. Henley et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD Eur Respir J 38 4 2011 Oct 797 803
8. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, and D. Jack et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 6 2010 Jun 473 479
9. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2 2011 Feb 273 279
10. C. Vogelmeier, D. Ramos-Barbon, D. Jack, S. Piggott, R. Owen, and M. Higgins et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium Respir Res 11 2010 Oct 5 135 10.1186/1465-9921-11-135
11. K.M. Beeh, D. Singh, S.L. Di, and A. Drollmann Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial Int J Chron Obstruct Pulmon Dis 7 2012 503 513
12. A. D'Urzo, G.T. Ferguson, J.A. van Noord, K. Hirata, C. Martin, and R. Horton et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir Res 12 2011 Dec 7 156 10.1186/1465-9921-12-156
13. E. Kerwin, J. Hebert, N. Gallagher, C. Martin, T. Overend, and V.K. Alagappan et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur Respir J 40 5 2012 Nov 1106 1114
14. R.G. Barr, J. Bourbeau, C.A. Camargo, and F.S. Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax 61 10 2006 Oct 854 862
15. A.M. Yohannes, T.G. Willgoss, and J. Vestbo Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes Respir Care 56 4 2011 Apr 477 487
16. GOLD Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2008 Available at: www.goldcopd.org
17. M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, and P.J. Barnes et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2 2008 Feb 416 469
18. J. Travers, P. Laveneziana, K.A. Webb, S. Kesten, and D.E. O'Donnell Effect of tiotropium bromide on the cardiovascular response to exercise in COPD Respir Med 101 9 2007 Sep 2017 2024
19. W.D. Man, N. Mustfa, D. Nikoletou, S. Kaul, N. Hart, and G.F. Rafferty et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD Thorax 59 6 2004 Jun 471 476
20. D.E. O'Donnell, R. Casaburi, W. Vincken, L. Puente-Maestu, J. Swales, and D. Lawrence et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD Respir Med 105 7 2011 Jul 1030 1036
21. F. Maltais, A. Hamilton, D. Marciniuk, P. Hernandez, F.C. Sciurba, and K. Richter et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD Chest 128 3 2005 Sep 1168 1178
22. M. Thomas, M. Decramer, and D.E. O'Donnell No room to breathe: the importance of lung hyperinflation in COPD Prim Care Respir J 22 1 2013 Mar 101 111
23. D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, and B. Aguilaniu et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur Respir J 23 6 2004 Jun 832 840
24. K.M. Beeh, F. Wagner, S. Khindri, and A.F. Drollmann Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD COPD 8 5 2011 Oct 340 345
25. PADAC Pulmonary-allergy drugs advisory Committee meeting 29 Jan, 2013 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM336760.pdf
26. J.A. Guenette, K.A. Webb, and D.E. O'Donnell Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J 40 2 2012 Aug 322 329
27. F. Maltais, S. Singh, A. Donald, G. Crater, A. Church, and A. Goh et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials Eur Respir Soc Annual Congress 2013 761
28. C.F. Vogelmeier, E.D. Bateman, J. Pallante, V.K.T. Alagappan, P. D'Andrea, and H. Chen et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Lancet Respir Med 1 1 2013 51 60
29. D. Deschenes, V. Pepin, D. Saey, P. LeBlanc, and F. Maltais Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease J Cardiopulm Rehabil Prev 28 3 2008 May 208 214
30. D.C. Berton, M. Reis, A.C. Siqueira, A.C. Barroco, L.S. Takara, and D.M. Bravo et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD Respir Med 104 9 2010 Sep 1288 1296
31. P.M. Calverley, F.J. Martinez, L.M. Fabbri, U.M. Goehring, and K.F. Rabe Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol Int J Chron Obstruct Pulmon Dis 7 2012 375 382
32. D.P. Tashkin, D.E. Doherty, E. Kerwin, C.E. Matiz-Bueno, B. Knorr, and T. Shekar et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials Int J Chron Obstruct Pulmon Dis 7 2012 73 86